Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology

The Biology of ALL: Subtypes and Genetic Markers

At a Glance

Acute Lymphoblastic Leukemia (ALL) is classified into B-cell and T-cell subtypes, each with specific genetic markers like the Philadelphia chromosome (Ph+). Identifying these markers is essential for doctors to create a personalized, targeted treatment plan for your specific leukemia.

To understand Acute Lymphoblastic Leukemia (ALL), it helps to think of your bone marrow as a factory that makes blood cells. In a healthy factory, “progenitor cells” (the early versions of white blood cells) grow up and go to work fighting infections. In ALL, a “malignant transformation” occurs—a genetic glitch that turns these healthy cells into cancer cells [1][2]. These cells stop maturing and start multiplying rapidly, crowding out the healthy cells your body needs [3].

The Two Main Subtypes: B-Cell vs. T-Cell

ALL is categorized based on which type of white blood cell “factory line” is affected.

  • B-Cell ALL (B-ALL): This is the most common form, especially in children [4]. It involves the B-lymphocytes, which normally produce antibodies to fight germs [1].
  • T-Cell ALL (T-ALL): This subtype involves T-lymphocytes, which normally act as the “soldiers” of the immune system by attacking infected cells directly [5]. T-ALL makes up about 10–15% of pediatric cases and 20% of adult cases [4]. It often requires a slightly different combination of medications [3].

The Philadelphia Chromosome (Ph+)

One of the most important genetic markers doctors look for is the Philadelphia chromosome, also known as Ph+. This happens when two pieces of DNA (from chromosomes 9 and 22) swap places, creating a “fusion gene” called BCR-ABL1 [6][7].

This fusion gene creates a protein that acts like a “stuck gas pedal,” telling the cancer cells to grow without stopping [8]. While Ph+ ALL was once very difficult to treat, the discovery of Tyrosine Kinase Inhibitors (TKIs)—targeted pills like imatinib or dasatinib—has changed everything [9][10]. These drugs specifically “unstick” the gas pedal, making treatment much more effective [11][12].

The “Ph-like” Subtype

Some patients have Ph-like ALL. This means their leukemia cells don’t have the BCR-ABL1 fusion, but they behave exactly like they do [13]. Because these cells use similar growth pathways, they are often considered “high-risk,” but they may also respond to the same targeted TKI drugs used for Ph+ patients [14][15].

Other Key Genetic Markers

Your doctor will look for several other “tags” on the cancer cells to determine how aggressive the treatment needs to be:

  • DUX4: Often associated with a “favorable” prognosis, meaning the cancer usually responds very well to standard treatment [16][17].
  • PAX5alt: This is a diverse group of markers. Some are associated with a higher risk of the cancer coming back, while others are more easily treated [18][16].
  • KMT2A: This marker is more common in infants and some adults. It is generally considered “unfavorable” and often requires a more intensive or specialized treatment approach [19][20].

Identifying these markers—a process called risk stratification—is the most important step in building your personalized treatment plan [21][22]. It ensures you get exactly the amount of treatment you need: enough to beat the cancer, but no more than necessary [23].

Common questions in this guide

What is the difference between B-cell and T-cell ALL?
B-cell ALL is the most common subtype and affects the cells that produce antibodies. T-cell ALL affects the cells that normally attack infected cells directly and often requires a different combination of medications.
What does it mean to be Philadelphia chromosome positive (Ph+) in ALL?
Being Philadelphia chromosome positive means your leukemia cells have a specific genetic fusion called BCR-ABL1. This genetic change makes the cancer cells grow rapidly, but it can be effectively treated with targeted drugs called tyrosine kinase inhibitors.
What is Ph-like Acute Lymphoblastic Leukemia?
Ph-like ALL means your leukemia cells behave like they have the Philadelphia chromosome, even though they lack the specific BCR-ABL1 fusion. Because they use similar growth pathways, these cases may also respond well to targeted therapies.
How do genetic markers like DUX4 or KMT2A affect my treatment?
Genetic markers help doctors determine your risk level and tailor your treatment plan. Markers like DUX4 often indicate a favorable response to standard treatment, while markers like KMT2A may require a more intensive therapeutic approach.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my leukemia been tested for the Philadelphia chromosome or the 'Ph-like' profile?
  2. 2.Which specific genetic mutations (like DUX4, PAX5, or KMT2A) were found in my bone marrow sample?
  3. 3.How do these genetic markers change the type of chemotherapy or targeted drugs I will receive?
  4. 4.When will we re-test these markers to see if the treatment is successfully clearing the 'blasts'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

    Vicente C, Cools J

    Haematologica 2015; (100(11)):1373-5 doi:10.3324/haematol.2015.136077.

    PMID: 26521295
  2. 2

    Lactic Acidosis in a Critically Ill Patient: Not Always Sepsis.

    Schuh AM, Leger KJ, Summers C, Uspal NG

    Pediatric emergency care 2018; (34(9)):e165-e167 doi:10.1097/PEC.0000000000001603.

    PMID: 30180106
  3. 3

    MYC degradation via AURKB inhibition: a new brake in the path to T-ALL.

    Zhang W, Pear WS

    Blood science (Baltimore, Md.) 2020; (2(2)):68-69 doi:10.1097/BS9.0000000000000046.

    PMID: 35402818
  4. 4

    CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

    Leong S, Inglott S, Papaleonidopoulou F, et al.

    Blood advances 2020; (4(19)):4665-4668 doi:10.1182/bloodadvances.2020002502.

    PMID: 33002130
  5. 5

    Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.

    Marchesini M, Gherli A, Montanaro A, et al.

    Cell chemical biology 2020; (27(6)):678-697.e13 doi:10.1016/j.chembiol.2020.04.002.

    PMID: 32386594
  6. 6

    From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.

    Thakral B, Jain N, Tang G, et al.

    Annals of diagnostic pathology 2021; (53()):151767 doi:10.1016/j.anndiagpath.2021.151767.

    PMID: 34118580
  7. 7

    Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization.

    L'Abbate A, Moretti V, Pungolino E, et al.

    Genes 2023; (14(7)) doi:10.3390/genes14071351.

    PMID: 37510256
  8. 8

    Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.

    Keramatinia A, Ahadi A, Akbari ME, et al.

    Journal of cancer prevention 2017; (22(2)):74-81 doi:10.15430/JCP.2017.22.2.74.

    PMID: 28698860
  9. 9

    Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

    Saleh K, Fernandez A, Pasquier F

    Cancers 2022; (14(7)) doi:10.3390/cancers14071805.

    PMID: 35406576
  10. 10

    [Research progress in Ph-like childhood acute lymphoblastic leukemia].

    Tang X, Guo X

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2017; (19(11)):1213-1218.

    PMID: 29132472
  11. 11

    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.

    Foà R, Bassan R, Elia L, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(8)):881-885 doi:10.1200/JCO.23.01075.

    PMID: 38127722
  12. 12

    Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

    Jabbour E, Short NJ, Jain N, et al.

    The Lancet. Haematology 2023; (10(1)):e24-e34 doi:10.1016/S2352-3026(22)00319-2.

    PMID: 36402146
  13. 13

    Can Ph-like ALL be effectively targeted?

    Maese L, Raetz EA

    Best practice & research. Clinical haematology 2019; (32(4)):101096 doi:10.1016/j.beha.2019.101096.

    PMID: 31779971
  14. 14

    BCR-ABL1-like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review.

    Jain S, Abraham A

    Archives of pathology & laboratory medicine 2020; (144(2)):150-155 doi:10.5858/arpa.2019-0194-RA.

    PMID: 31644323
  15. 15

    BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.

    Płotka A, Lewandowski K

    Acta haematologica 2022; (145(2)):122-131 doi:10.1159/000519782.

    PMID: 34818644
  16. 16

    Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic Leukemia.

    Yu CH, Wu G, Chang CC, et al.

    The Journal of molecular diagnostics : JMD 2022; (24(11)):1195-1206 doi:10.1016/j.jmoldx.2022.08.001.

    PMID: 35963521
  17. 17

    DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.

    Bakewell J, Moorman AV, Ryan SL

    Leukemia 2025; (39(12)):2835-2847 doi:10.1038/s41375-025-02758-5.

    PMID: 40940582
  18. 18

    PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

    Gu Z, Churchman ML, Roberts KG, et al.

    Nature genetics 2019; (51(2)):296-307 doi:10.1038/s41588-018-0315-5.

    PMID: 30643249
  19. 19

    Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following Blinatumomab Therapy.

    Du J, Chisholm KM, Tsuchiya K, et al.

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2021; (24(4)):378-382 doi:10.1177/10935266211001308.

    PMID: 33749383
  20. 20

    Multiple Lineage Switches in a Pediatric Case With a KMT2A::AFF1-Positive Acute Lymphoblastic Leukemia: How Cell Plasticity Induces Immunotherapy Failure.

    Lo Nigro L, Arrabito M, Cannata E, et al.

    Pediatric blood & cancer 2025; (72(10)):e31950 doi:10.1002/pbc.31950.

    PMID: 40879568
  21. 21

    Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

    Jeha S, Choi J, Roberts KG, et al.

    Blood cancer discovery 2021; (2(4)):326-337 doi:10.1158/2643-3230.BCD-20-0229.

    PMID: 34250504
  22. 22

    Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.

    Paietta E, Roberts KG, Wang V, et al.

    Blood 2021; (138(11)):948-958 doi:10.1182/blood.2020010144.

    PMID: 33895809
  23. 23

    A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

    Keeney M, Wood BL, Hedley BD, et al.

    Cytometry. Part B, Clinical cytometry 2018; (94(2)):239-249 doi:10.1002/cyto.b.21528.

    PMID: 28475275

This page explains Acute Lymphoblastic Leukemia (ALL) subtypes and genetics for educational purposes. Your oncologist and hematologist are the best resources for interpreting your specific pathology report and treatment plan.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.